CDMOs Step Up Parenteral Manufacturing Support

With the pharmaceutical industry’s growing pipeline of biologics, products often delivered parenterally, and the impact of the COVID pandemic and vaccine production, the need for technically advanced manufacturing support has grown considerably and contract development and manufacturing organizations (CDMOs) are playing a vital role.

Throughout the pandemic, CDMOs of all sizes and capabilities stepped in to fulfil industry needs, providing the capabilities and capacities for the manufacture of essential medicines.

Jeff Clement, Executive Director, CDMO Business Development North America, PCI Pharma Services discusses the impact of the pandemic on CDMOs and parenteral market trends.